Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
NVST or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
Boston Scientific's (BSX) New Buyout to Aid Clot Management
by Zacks Equity Research
The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
Abbott's (ABT) Portico With FlexNav System Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
by Zacks Equity Research
Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line
by Zacks Equity Research
Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
by Zacks Equity Research
Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.
Why Is Boston Scientific (BSX) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Boston Scientific (BSX) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
NVST or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Top Research Reports for Amazon, Pfizer & Verizon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Pfizer Inc. (PFE), and Verizon Communications Inc. (VZ).
4 Medical Device Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.
Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.
Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.
Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
by Zacks Equity Research
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up
by Zacks Equity Research
Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.